Malignant Mesothelioma Drug Pipeline Analysis Report 2025

The mesothelium is the protective lining of internal organs. It is where malignant mesothelioma, an uncommon and aggressive disease, forms. Though it can also occur in the peritoneum (the lining of the abdomen), pericardium (the lining of the heart), and tunica vaginalis (the lining of the testicles), it mainly affects the pleura (the lining of the lungs). Exposure to asbestos is the main cause, and symptoms may appear 20-60 years later. The location affects the symptoms, which can include swelling, shortness of breath, chest pain, and abdominal pain. It is a malignancy that is thought to be fatal, and the prognosis is typically poor. Moreover, its rising prevalence is anticipated to positively impact the pipeline landscape for malignant mesothelioma drugs.

Report Coverage

The Malignant Mesothelioma Drug Pipeline Insight Report by the publisher gives comprehensive insights into malignant mesothelioma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for malignant mesothelioma. The malignant mesothelioma report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The malignant mesothelioma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with malignant mesothelioma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to malignant mesothelioma.

Malignant Mesothelioma Drug Pipeline Outlook

Malignant mesothelioma is caused by the neoplastic transformation of mesothelial cells, which is frequently brought on by asbestos exposure. Normal cell growth regulation is disrupted by the frequent inactivation or deletion of important tumor suppressor genes, including p16INK4a, p14ARF, NF2, and BAP1. Cell survival and proliferation are fueled by chromosomal anomalies and dysregulation of signaling networks, including the PI3K-AKT, Raf-MEK-ERK, and Hippo pathways. Protein synthesis is improved, and metabolic outputs are reprogrammed by increased translation of mRNAs for ribosome assembly and mitochondrial biogenesis, which further encourages tumor growth. The development of mesothelioma is also influenced by angiogenesis, which is fueled by substances such as vascular endothelial growth factor.

The most preferred type of molecule for the treatment of malignant mesothelioma is small molecule inhibitors, particularly immune checkpoint inhibitors (ICIs) like nivolumab and ipilimumab. These drugs target PD-1/PD-L1 pathways, enhancing the immune system’s ability to attack cancer cells. Small molecules like tyrosine kinase inhibitors (TKIs) are also being explored for targeted therapy. Their advantages include oral bioavailability, specificity, and effectiveness in controlling tumor progression, making them a key component of mesothelioma treatment alongside chemotherapy and immunotherapy. Further, the rising focus on the development of malignant mesothelioma emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.

Malignant Mesothelioma Epidemiology

About 3,000 new cases of malignant mesothelioma are discovered in the US each year, making it a rare cancer. In 2019, it made up fewer than 0.2% of all cancer diagnoses in the United States. In the United States, 72,779 new cases were detected between 1999 and 2021. White, Hispanic, and Latino individuals have a higher incidence of mesothelioma. Pleural mesothelioma is diagnosed at an average age of 72, making it more prevalent in older people. Higher percentages are found in states like California that have a history of industrialization or natural asbestos deposits.

Malignant Mesothelioma - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of malignant mesothelioma drug candidates based on several segmentations including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecule
• Gene Therapy
• Stem Cell Therapy
• Antidepressants
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Malignant Mesothelioma - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials, with a substantial number of malignant mesothelioma drugs undergoing clinical development.

Malignant Mesothelioma - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under malignant mesothelioma pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The malignant mesothelioma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for malignant mesothelioma.

Malignant Mesothelioma Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the malignant mesothelioma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed malignant mesothelioma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in malignant mesothelioma clinical trials:

• MedImmune LLC.
• Epizyme Inc.
• Ferring Ventures Limited
• TCR2 Therapeutics
• Checkpoint Therapeutics, Inc.
• Compass Therapeutics
• NGM Biopharmaceuticals, Inc
• iOnctura

Malignant Mesothelioma Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: rAd-IFN

Ferring Ventures Limited is conducting a Phase 3 clinical trial to assess the efficacy and safety of rAd-IFN, an adenovirus-delivered interferon alpha-2b gene therapy, in combination with celecoxib and gemcitabine for treating malignant pleural mesothelioma. The study involves intrapleural administration of rAd-IFN, aiming to enhance anti-tumor responses. Participants receive rAd-IFN and celecoxib, followed by gemcitabine, with the primary objective of comparing overall survival against a control group receiving only celecoxib and gemcitabine. The trial began in January 2019 and is expected to complete by April 2026.

Drug: Tazemetostat

Tazemetostat, developed by Epizyme Inc., is an oral EZH2 inhibitor under investigation for treating malignant mesothelioma. A Phase 2, open-label study evaluated its efficacy in patients with relapsed or refractory malignant pleural mesothelioma characterized by BAP1 loss-of-function. The trial reported a 54% disease control rate at 12 weeks, with partial responses observed in some patients. Tazemetostat was generally well-tolerated, with manageable side effects such as fatigue and nausea. These findings suggest the potential benefits of tazemetostat for this patient population.

Reasons To Buy This Report

The Malignant Mesothelioma Drug Report provides a strategic overview of the latest and future landscape of treatments for malignant mesothelioma. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the malignant mesothelioma pipeline insights.

Key Questions Answered in the Malignant Mesothelioma - Pipeline Insight Report

• What is the current landscape of malignant mesothelioma pipeline drugs?
• Which companies/institutions are developing malignant mesothelioma emerging drugs?
• How many phase II drugs are currently present in malignant mesothelioma pipeline drugs?
• Which company is leading the malignant mesothelioma pipeline development activities?
• What is the current malignant mesothelioma therapeutic assessment?
• What are the opportunities and challenges present in the malignant mesothelioma drug pipeline landscape?
• What is the efficacy and safety profile of malignant mesothelioma pipeline drugs?
• Which companies/institutions are involved in malignant mesothelioma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in malignant mesothelioma?

This product will be delivered within 3-5 business days.